Production (Stage)
NLS Pharmaceutics AG
NLSP
$2.30
$0.2210.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 27.50K | 27.50K | -1.02M | -1.02M | -2.28M |
| Total Depreciation and Amortization | -1.20K | -1.20K | 2.90K | 2.90K | 2.90K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.23M | -1.23M | 49.70K | 49.70K | 89.70K |
| Change in Net Operating Assets | -161.30K | -161.30K | 200.10K | 200.10K | 993.20K |
| Cash from Operations | -1.37M | -1.37M | -765.20K | -765.20K | -1.19M |
| Capital Expenditure | -2.00K | -2.00K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -2.00K | -2.00K | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | 816.90K |
| Total Debt Repaid | 97.40K | 97.40K | -97.40K | -97.40K | -- |
| Issuance of Common Stock | 2.02M | 2.02M | 690.10K | 690.10K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -193.20K | -193.20K | -- | -- | -- |
| Cash from Financing | 1.93M | 1.93M | 592.80K | 592.80K | 816.90K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | 200.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 556.30K | 556.30K | -172.50K | -172.50K | -376.90K |